JP5380455B2 - 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用 - Google Patents

置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用 Download PDF

Info

Publication number
JP5380455B2
JP5380455B2 JP2010530054A JP2010530054A JP5380455B2 JP 5380455 B2 JP5380455 B2 JP 5380455B2 JP 2010530054 A JP2010530054 A JP 2010530054A JP 2010530054 A JP2010530054 A JP 2010530054A JP 5380455 B2 JP5380455 B2 JP 5380455B2
Authority
JP
Japan
Prior art keywords
methyl
phenyl
bipyrrolidinyl
carboxylic acid
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010530054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500697A5 (enExample
JP2011500697A (ja
Inventor
ヴェルンガルト・チェヒティツキ
チョンリー・ガオ
ウィリアム・ジェイ・ハースト
ロータール・シュヴィンク
ジークフリート・シュテンゲリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2011500697A publication Critical patent/JP2011500697A/ja
Publication of JP2011500697A5 publication Critical patent/JP2011500697A5/ja
Application granted granted Critical
Publication of JP5380455B2 publication Critical patent/JP5380455B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2010530054A 2007-10-17 2008-10-14 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用 Expired - Fee Related JP5380455B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98060607P 2007-10-17 2007-10-17
US60/980,606 2007-10-17
PCT/US2008/079763 WO2009052068A1 (en) 2007-10-17 2008-10-14 Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof

Publications (3)

Publication Number Publication Date
JP2011500697A JP2011500697A (ja) 2011-01-06
JP2011500697A5 JP2011500697A5 (enExample) 2011-12-01
JP5380455B2 true JP5380455B2 (ja) 2014-01-08

Family

ID=40248052

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530054A Expired - Fee Related JP5380455B2 (ja) 2007-10-17 2008-10-14 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用

Country Status (24)

Country Link
US (1) US8222290B2 (enExample)
EP (1) EP2215058B1 (enExample)
JP (1) JP5380455B2 (enExample)
KR (1) KR20100082349A (enExample)
CN (1) CN101903341B (enExample)
AT (1) ATE534625T1 (enExample)
AU (1) AU2008312641A1 (enExample)
CA (1) CA2702933C (enExample)
CY (1) CY1112391T1 (enExample)
DK (1) DK2215058T3 (enExample)
ES (1) ES2378011T3 (enExample)
HR (1) HRP20120166T1 (enExample)
IL (1) IL205002A0 (enExample)
MA (1) MA31889B1 (enExample)
MX (1) MX2010003948A (enExample)
MY (1) MY148807A (enExample)
NZ (1) NZ584692A (enExample)
PL (1) PL2215058T3 (enExample)
PT (1) PT2215058E (enExample)
RS (1) RS52221B (enExample)
RU (1) RU2478094C2 (enExample)
SI (1) SI2215058T1 (enExample)
WO (1) WO2009052068A1 (enExample)
ZA (1) ZA201002114B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525351T1 (de) 2007-10-17 2011-10-15 Sanofi Sa Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
CA2702482C (en) 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
WO2009052063A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
KR20090129927A (ko) 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
CN101983181B (zh) * 2008-06-13 2015-10-14 Lg化学株式会社 加热件及其制备方法
WO2011143163A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
EP2569280B1 (en) 2010-05-11 2015-02-25 Sanofi Substituted phenyl cycloalkyl pyrrolidine (piperidine) spirolactams and amides, preparation and therapeutic use thereof
TW201206444A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
WO2011143145A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-alkyl and n-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201202251A (en) 2010-05-11 2012-01-16 Sanofi Aventis Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
JP2013529198A (ja) 2010-05-11 2013-07-18 サノフイ 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
EP2569294B1 (en) * 2010-05-11 2015-03-11 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
UY33726A (es) 2010-11-15 2012-06-29 Abbott Lab Inhibidores de nampt y rock
JP5805792B2 (ja) * 2011-02-23 2015-11-10 スヴェン・ライフ・サイエンシズ・リミテッド ヒスタミンｈ３レセプターリガンドとしての新規な化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
JP2006505590A (ja) * 2002-10-23 2006-02-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体調節物質としてのフェニルピペリジンおよびフェニルピロリジン
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
MX2007011374A (es) 2005-03-17 2007-11-23 Lilly Co Eli Derivados de pirrolidina como antagonistas del receptor histamina h3.
CN101151244B (zh) * 2005-04-01 2014-09-03 伊莱利利公司 组胺h3受体活性剂、制备和治疗用途
JP5193033B2 (ja) * 2005-07-01 2013-05-08 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体薬剤、製剤及び治療的使用
WO2007048595A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
ATE525351T1 (de) 2007-10-17 2011-10-15 Sanofi Sa Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
WO2009052063A1 (en) 2007-10-17 2009-04-23 Sanofi-Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
CA2702482C (en) 2007-10-17 2012-11-27 Sanofi-Aventis Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Also Published As

Publication number Publication date
US20100173908A1 (en) 2010-07-08
RU2478094C2 (ru) 2013-03-27
MX2010003948A (es) 2010-04-30
MA31889B1 (fr) 2010-12-01
DK2215058T3 (da) 2012-03-12
PL2215058T3 (pl) 2012-04-30
WO2009052068A1 (en) 2009-04-23
CA2702933C (en) 2012-12-18
RS52221B (sr) 2012-10-31
NZ584692A (en) 2011-12-22
HRP20120166T1 (hr) 2012-03-31
RU2010119554A (ru) 2011-11-27
CY1112391T1 (el) 2015-12-09
KR20100082349A (ko) 2010-07-16
JP2011500697A (ja) 2011-01-06
ATE534625T1 (de) 2011-12-15
MY148807A (en) 2013-05-31
CN101903341A (zh) 2010-12-01
ZA201002114B (en) 2010-12-29
SI2215058T1 (sl) 2012-03-30
US8222290B2 (en) 2012-07-17
EP2215058B1 (en) 2011-11-23
ES2378011T3 (es) 2012-04-04
EP2215058A1 (en) 2010-08-11
CA2702933A1 (en) 2009-04-23
HK1146056A1 (en) 2011-05-13
CN101903341B (zh) 2012-10-03
AU2008312641A1 (en) 2009-04-23
PT2215058E (pt) 2012-03-06
IL205002A0 (en) 2010-11-30

Similar Documents

Publication Publication Date Title
JP5380455B2 (ja) 置換されたｎ−フェニル−ビピロリジン尿素及びその治療上の使用
JP5377503B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
JP5255644B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
JP5377504B2 (ja) 置換されたｎ−フェニル−ピロリジニルメチルピロリジンアミドおよびその治療的用途
JP5784110B2 (ja) 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用
JP2013529198A (ja) 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用
HK1146056B (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
HK1146053B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130930

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees